ASX/Media Release
4 February 2022

Release of Securities from Escrow

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech developing multiple treatments for unmet needs powered by real-world patient data, notifies ASX, in accordance with Listing Rule 3.10A, that 100,097,478 Ordinary Shares and 10,500,000 unlisted options exercisable at $0.45 on or before 13 June 2023 will be released from escrow on 12 February 2022.

Approximately 75% of the Ordinary Shares being released from escrow are held by the directors and management of the Company, or their nominees.

Release authorised by the Company Secretary of the Company

For further information on Emyria, please contact:

Dr. Michael Winlo	Lexi O'Halloran	Andrew Williams
Managing Director	**Investor Relations**	**Media Relations**
1300 436 363	+ 61 (0) 404 577 076	+61 (0) 412 614 125
mwinlo@emyria.com	lexi@janemorganmanagement.com.au	andreww@profilemedia.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

Emyria's Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.